Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$63.96 USD

63.96
24,069,834

+2.16 (3.50%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $64.03 +0.07 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (153 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline

by Zacks Equity Research

Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Moderna (MRNA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Moderna (MRNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?

by Zacks Equity Research

Strong Dupixent profits and rising Eylea HD demand may help Regeneron offset pressure in its Q2 earnings report.

Zacks Equity Research

Moderna (MRNA) Stock Slides as Market Rises: Facts to Know Before You Trade

by Zacks Equity Research

In the latest trading session, Moderna (MRNA) closed at $34.01, marking a -1.9% move from the previous day.

Zacks Equity Research

Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?

by Zacks Equity Research

Sector ETF report for RSPH

Zacks Equity Research

Here's Why Moderna (MRNA) Fell More Than Broader Market

by Zacks Equity Research

In the most recent trading session, Moderna (MRNA) closed at $31.25, indicating a -2.95% shift from the previous trading day.

Zacks Equity Research

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks Equity Research

FDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger Adults

by Zacks Equity Research

FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.

Zacks Equity Research

Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights

by Zacks Equity Research

The latest trading day saw Moderna (MRNA) settling at $33.64, representing a -1.87% change from its previous close.

Zacks Equity Research

MRNA Stock Up on Full FDA Nod for COVID-19 Jab in Pediatric Patients

by Zacks Equity Research

Moderna stock jumps 4.5% as the FDA grants full approval for its COVID-19 vaccine in high-risk individuals aged six months to 11 years.